Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Lexston Life Sciences Corp. (C:LEXT)

Business Focus: N/A

May 13, 2022 03:45 pm ET
LEXSTONS Directors Approve Five to One Share Consolidation
Vancouver, British Columbia – TheNewswire - May 13, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (OTC:LEXTF) announces that its board of directors approved the consolidation of the common shares of the Company on the ratio of five (5) pre-consolidated shares for one (1) post-consolidated share.  The effective date and timing of the share consolidation will be determined and announced at a later date.
Apr 11, 2022 07:00 am ET
Lexston Life Sciences funds whole genome sequencing project for Psilocybe allenii, an understudied psychedelic mushroom native to the Pacific Northwest
Vancouver, British Columbia - TheNewswire - April 11, 2022 - Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) a biotechnology company focused on the development of analytical services and production of botanically derived psychedelics, is pleased to announce that, on April 4, 2022, its wholly-owned subsidiary, Egret Bioscience Ltd., sponsored the whole genome sequencing, open access archiving and biobanking of the Pacific Northwest wood-rotting psychedelic mushroom, Psilocybe allenii.
Mar 25, 2022 02:40 pm ET
LEXSTON LIFE SCIENCES CORP. Appoints CFO, Makes Changes to the Audit Committee
Vancouver, British Columbia – TheNewswire - March 25, 2022. Lexston Life Sciences Corp. (CSE:LEXT) (the “Company” or “Lexston”) announces the resignation of Dimitrios Mitrakos as the Chief Financial Officer and Corporate Secretary of the Company and the appointment of Company’s director Jatinder Jesse Manhas as the Chief Financial Officer and Corporate Secretary of the Company.
Jan 31, 2022 06:00 am ET
Lexston Life Sciences is Granted Section 56 Exemption from Health Canada and embarks on the development of portable technology for quantification and traceability of Psilocybe mushrooms
Vancouver – TheNewswire - British Columbia, January 31, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTCQB:LEXTF) a biotechnology company focused on the development of analytical services and production of botanically derived psychedelics, is pleased to announce that, on January 17, 2022, its wholly-owned subsidiary, Egret Bioscience Ltd., was granted a two year long Section 56 exemption by Health Canada, pursuant to which the company can now possess up to 100 grams of psilocybin mushrooms for scientific purposes for their project entitled “Establi
Jan 24, 2022 06:30 am ET
Lexston Announces The Launch Of A Psychedelic Mushrooms Genetic Identification Test
Vancouver, British Columbia - TheNewswire - January 24, 2022 - Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) is pleased to announce that the Company’s wholly owned subsidiary, Egret Bioscience Ltd. (“Egret”) has developed and validated a targeted genetic barcode consisting of eight Single Nucleotide Polymorphism (“SNP”) for psychedelic mushroom genetic identification (“Egret Psilocybe Assay”).  Egret has previously developed and published similar genetic identification tests for the Cannabis Industry (https://t.co/rh1VJ5cf0a) and have been offe
Jan 19, 2022 04:00 am ET
Lexston Announces Federal Funding for Cannabis Transformation Project That Will Result in Zero THC Varieties.
Vancouver, British Columbia – TheNewswire - January 19, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTCQB:LEXTF) is pleased to announce that the company’s wholly owned subsidiary, Egret Bioscience Ltd. (“Egret”) has recently received funding from the Canadian government for their project on Cannabis transformation to develop new breeding techniques using CRISPR-Cas9 technology.
Jan 14, 2022 04:00 pm ET
Lexston Comments On Recent Market Activity
Vancouver, British Columbia – TheNewswire - January 14, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF)  wishes to make the following statements regarding certain market activity surrounding its common shares (the” Shares”) traded on the OTCQB market pursuant to the request of OTC Markets Group Inc. (“OTC Markets”).
Jan 12, 2022 06:30 am ET
Lexston Announces a Memorandum Of Understanding to Collabborate on Psychedelics Research and Development with Alvarius Research Inc.
Vancouver, British Columbia – TheNewswire - January 12, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) is pleased to announce the signing of a Memorandum of Understanding (the “MOU”) between its wholly owned subsidiary Egret Bioscience Ltd. (“Egret”) and Alvarius Research Inc. (“Alvarius”; a wholly owned subsidiary of Lighthouse Genomics Inc.), a leading research and development company focused on ex situ conservation and genomic resource development for the Colorado River toad (Incilius alvarius).
Jan 10, 2022 06:30 am ET
Lexston Announces a Memorandum of Understanding with United States Based Panacea Plant Sciences Inc. for Research and Development of Psychedelics and Cannabis
\Vancouver, British Columbia - TheNewswire - January 10, 2022 - Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) is pleased to announce the signing of a Memorandum of Understanding (the “MOU”) between its wholly owned subsidiary Egret Bioscience Ltd. (“Egret”) and Panacea Plant Sciences Inc. (“Panacea”), a leading United States biotechnology company focused on developing new therapeutic, cultivation, extraction and isolation techniques for high value natural products such as psychedelic-containing lifeforms and cannabis.
Dec 15, 2021 07:00 am ET
Lexston Life Sciences Corp. announces DTC Eligibility
Vancouver, British Columbia - TheNewswire - December 15th, 2021 - Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.
Nov 15, 2021 09:00 am ET
Lexston Life Sciences Corp. Announces Upgrade to OTCQB Market in the United States
Vancouver, British Columbia – TheNewswire - November 15, 2021 - Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) (the “Company” or “Lexston”) is pleased to announce that after successfully completing the application process, the Company has received approval from OTC Markets Group Inc. for its common shares to begin trading on the OTCQB Market ("OTCQB") beginning at market open on November 12, 2021 under the symbol "LEXTF". The Company's common shares will remain listed on the CSE in Canada under the ticker symbol "LEXT".
Nov 11, 2021 04:40 pm ET
Lexston Life Sciences Corp. Grants Stock Options
Vancouver, British Columbia – TheNewswire - November 11, 2021. Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (“Lexston”) granted 1,400,000 stock options to its directors, officers, consultants and employees.  
Sep 28, 2021 05:50 am ET
Lexston Life Sciences Corp. Congratulates Psy Integrated Health Inc.
Vancouver, British Columbia - TheNewswire - September 28, 2021 - Lexston Life Sciences Corp. (CNSX:LEXT.CN) (OTC:LEXTF) (the “Company” or “Lexston”) is pleased to announce that further to the news of July 7th, 2021 announcing the acquisition of 750,000 Class C Non-Voting Common Shares for a total of 13% ownership of Psy Integrated Health Inc. (“Psy Integrated”), Psy Integrated has celebrated their grand opening of its  state of the art health and wellness center, Empower Health Clinic, in Vancouver, British Columbia on September 18, 2021.
Sep 23, 2021 05:45 am ET
Lexston Initiates Research and Development Project Using Psychedelic Compound 5-Me0-DMT
Vancouver, British Columbia - TheNewswire - September 23, 2021 - Lexston Life Sciences Corp. (CNSX:LEXT.CN) (the “Company” or “Lexston”) is pleased to announce that the company’s scientific research and development division led by Chief Science Officer, Dr. Philippe Henry, has begun work on its tryptamine pipeline with an initial focus on 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) at its newly acquired Zenalytic Laboratories.
Sep 21, 2021 05:50 am ET
Lexston Life Sciences Corp. Acquires Zenalytic Laboratories Ltd.
Vancouver, British Columbia, September 21, 2021. Lexston Life Sciences Corp. (CSE: LEXT) (the “Company” or “Lexston”) is pleased to announce the acquisition of Zenalytic Laboratories Ltd. (“Zen Labs”), a wholly owned subsidiary of Avant Brands Inc. (“Avant”), which is a publicly listed issuer on the Toronto Stock Exchange (TSX: AVNT).
Sep 21, 2021 05:50 am ET
Lexston Life Sciences Corp. Acquires Zenalytic Laboratories Ltd.
Vancouver, British Columbia – TheNewswire - September 21, 2021 - Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (the “Company” or “Lexston”) is pleased to announce the acquisition of Zenalytic Laboratories Ltd. (“Zen Labs”), a wholly owned subsidiary of Avant Brands Inc. (“Avant”), which is a publicly listed issuer on the Toronto Stock Exchange (TSX: AVNT).
Sep 09, 2021 06:00 am ET
Lexston Life Sciences Corp. retains marketing consultants and sets Stock Options
Vancouver, British Columbia - TheNewswire - September 9, 2021 - Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CNSX:LEXT.CN) is pleased to announce that the Company has retained Amherst Baer Consultancy Corp. (ABCC”), of Langley, British Columbia, to prepare a marketing campaign for the Company.    
Jul 13, 2021 06:07 am ET
Lexston Life Sciences Corp. Health Canada Section 56 Exemption Application
Vancouver, British Columbia - TheNewswire - July 13, 2021 - Lexston Life Sciences Corp. (CNSX:LEXT.CN) (the “Company” or “Lexston”) is pleased to announce that on July 9, 2021, the Company received an update from Health Canada, that the application of its wholly owned subsidiary Egret Bioscience Ltd. (“Egret”) submitted to Health Canada for an exemption to use a controlled substance for scientific purposes, pursuant to Section 56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (a "Section 56 Exemption") has been screened and sent to the Office of Controlled Substances.  Lexsto
Jul 07, 2021 07:07 am ET
Lexston Life Sciences Corp. Makes an Investment Into Psy Integrated Health Inc.
Vancouver, British Columbia - TheNewswire - July 7, 2021 - Lexston Life Sciences Corp. (CNSX:LEXT.CN) (the “Company” or “Lexston”) is pleased to announce an acquisition of 750,000 Class C Non- Voting Common Shares of Psy Integrated Health Inc. (“Psy Integrated”) for the total consideration of $75,000 representing 13% of the total  issued and outstanding shares of Psy Integrated.
Jul 05, 2021 02:07 am ET
Lexston Life Sciences Corp. Grants Stock Options
Vancouver, British Columbia – TheNewswire - July 5, 2021 - Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (“Lexston”) granted 2,500,000 stock options to its directors, officers, consultants and employees.  
Jun 30, 2021 06:06 am ET
Lexston Life Sciences Corp. Appoints Graeme Staley to its Board of Directors
Vancouver, British Columbia – TheNewswire - June 30, 2021 - Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (the “Company” or “Lexston”) is pleased to announce the appointment of Mr. Graeme Staley to its board of directors.
Jun 23, 2021 04:12 pm ET
CSE Bulletin: New Listing - Lexston Life Sciences Corp. (LEXT)
Toronto, Ontario--(Newsfile Corp. - Le 23 juin/June 2021) The common shares of Lexston Life Sciences Corp. have been approved for listing on the CSE.
Jun 23, 2021 11:06 am ET
Lexston Life Sciences Corp. Announces Listing of its Common Shares on the Canadian Securities Exchange
Vancouver, British Columbia – TheNewswire - JUNE 23, 2021 - Lexston Life Sciences Corp. (the “Company”) (CNSX:LEXT.CN) is pleased to announce that its common shares will commence trading at market open on June 25, 2021 on the Canadian Securities Exchange under the stock symbol “LEXT”.